关于我们    —

About Us

粤港澳干细胞生物科技有限公司  GHM Stem Cell Biotechnology Co., Ltd

图片展示

公司概况

       东莞粤港澳干细胞生物科技有限公司,注册资金1亿元,专注于细胞储存、生物技术研发、以及细胞相关临床前研究。公司立足粤港澳大湾区,旗下已成立多家子公司与东莞市恩联干细胞生物科技研究院,并于2019年10月24日正式签约成为国家干细胞转化资源库的共建单位,致力带动生命科学与卫生医疗产业的健康发展。

       公司主要股东为广东名店集团、银帝集团以及杰出海归科学家。广东名店集团扎根东莞20多年,主营业务范围涉及生命科学、高新科技、大型房地产开发、金融投资等领域,董事长陈路为东莞十五届人大常委、东莞工商联副主席、广东省浙江商会执行会长、东莞浙江商会会长。银帝集团,企业注册资金39亿元。集团总部位于北京CBD核心区,董事局主席朱奕龙为中国侨联副主席、全国政协委员,同时担任粤港澳大湾区产融投资有限公司(注册资本400亿元)董事局主席兼总裁 。联合创始人李治寰博士,清华大学学士、研究生,美国罗切斯特大学博士,耶鲁大学、哈佛大学博士后,2014年获美国遗传学会Larry Sandler奖第二名,2017年入选深圳市海外高层次人才“孔雀计划”,具有国内外顶尖学术背景和资本市场经验。

       粤港澳干细胞生物科技先后与中国科学院深圳先进技术研究院、同济大学生命科学与技术学院、香港大学李嘉诚医学院、上海市东方医院、以及广州医科大学附属第一医院在共建联合实验室、共同研发项目、引进国内外高新技术人才等领域进行深度合作。

       东莞市恩联干细胞生物科技研究院,由东莞粤港澳干细胞生物科技有限公司与中国科学院广州生物医药与健康研究院于2018年8月联合建设,主管单位为东莞市科技局。目前已严格按照国家GMP标准和美国AABB标准建成一期4000平方米的实验室,配备世界一流的仪器设备,包括德国蔡司公司生产的激光共聚焦显微镜、美国GT医疗公司生产的BioArchive低温存储罐、默克公司生产的Flowsight流式细胞仪、美国Thermo公司生产的程序降温仪、迈瑞公司生产的血细胞分析仪等等。

       恩联研究院积极引进海內外顶尖专家与人才,研发团队阵容强大,包括:谭蔚泓(中国科学院院士)、ANTONIO VIDAL-PUIG(英国医学科学院院士、剑桥大学教授)、何建行(广东省心血管病研究所博士)、高绍荣(中国科学院动物研究所博士)、李治寰(美国罗切斯特大学博士、哈佛大学、耶鲁大学博士后)、阮建波(东莞市名医、特色人才)、康九红(国家杰出青年、长江学者)、康铁邦(教育部“长江学者”特聘教授)、夏建川(哈佛大学助理研究员)、朱麟勇(国家杰出青年、“东方学者”特聘教授)、万晓春(加拿大蒙特利尔大学博士)、畅君雷(美国哈佛医学院博士)、林同香(美国加州大学圣地亚哥分校博士后)、贾文文(西北农林科技大学和美国宾夕法尼亚大学联合培养博士)、楼陆军(南部战区空军医院专家组成员)、陈志凌(苏黎世联邦理工学院、欧洲核子研究中心博士)、刘星吟(美国罗切斯特大学和爱因斯坦医学院博士后)、ROBERT KONRAD NAUMANN(德国柏林洪堡大学博士、德国法兰克福马克斯普朗克脑研究所博士后)等。

       目前,恩联研究院已申请了多项生物技术发明专利,并获得广州市微生物研究所的GMP实验室清洁度与东莞市食品药品检验所清洁度的权威认证,同时通过了ISO9001、ISO14001、OHSAS18001质量体系认证,在细胞标准化制备、安全存储以及技术支持服务上已达到国际标准。恩联研究院已被推举为广东省细胞生物学学会副理事长单位,并被吸纳为中国生物医药技术协会会员。

       2019年8月,东莞市卫生健康局明确支持恩联研究院实施3年战略目标“2+5+2计划”,即恩联干细胞研究院在未来三年内:将至少联合东莞2家医院获得干细胞临床研究备案机构;联合东莞医院在国家卫健委备案5个细胞相关项目;联合东莞的医院提交2个细胞新药的临床批件申请。该计划的实施对促进干细胞与再生医学技术创新、成果转化和产业发展,助推东莞开展细胞治疗具有重要意义。目前,研究院与国内多家三甲医院及医疗机构合作共建再生医学生物资源库,如:上海市东方医院、广州医科大学附属第一医院、东莞市人民医院等19家公立医院,为实现“健康中国梦”持续贡献力量。


公司和研究院经营与研究范围包括:

公司和研究院经营与研究范围包括:

1. 细胞储存:脐带、脂肪、胎盘、牙髓间充质干细胞和免疫细胞的储存业务;

2. 细胞技术服务:临床级人源细胞技术科研服务;

3. 生物技术研发:新型干细胞及免疫细胞制备制剂技术研发、临床级细胞制备存储新技术和相关试剂的研发;

4. 细胞相关临床前研究:细胞分子机理研究、细胞疗法、细胞创新药物研发、细胞抗衰老研究等。

     GHM Stem Cell Biotechnology Co., Ltd. (GHMSCB), founded with registered capital of 100 million RMB, focuses on cell storage, biotechnology research and development, and cell related preclinical studies. GHM has several subsidiaries and Dongguan Enlife Stem Cell Biotechnology Institute (Enlife Institute). On 24 Oct 2019, GHM officially became the co-construction partner of the National Stem Cell Transformation Resource Bank, to promote the development of life sciences and healthcare industry.

The main shareholders of GHMSCB are Guang Dong Mingdian Group, Yindi Group and distinguished scientists. Guang Dong Mingdian Group has been operated in Dongguan City for more than 20 years, and its main business covers biotechnology, large-scale real estate projects, financial investment, etc. Chairman of the group, Lu Chen is the Vice Chairman of Industry and Commerce Federation of Dongguan City, Executive Chairman of Zhejiang Chamber of Commerce of Guangdong Province, and Chairman of Zhejiang Chamber of Commerce of Dongguan. Yindi Group, with registered capital of 3.9 billion RMB, is headquartered in the core of Beijing CBD. Chairman of the Board of Directors Mr. YiLong Zhu serves as Vice-Chairman of All-China Federation of Returned Overseas Chinese and member of the CPPCC National Committee. He is also Chairman and President of the Board of Directors of Guangdong-Hong Kong-Macao Greater Bay Area Investment Co., Ltd. (registered capital of 40 billion RMB). Co-founder Dr. Zhihuan Li received his B.S. from Tsinghua University and Ph.D. from the University of Rochester, and continued his Post-doctoral training in Yale University and Harvard University. He won the second place of Larry Sandler Memorial Award of the American Genetic Society in 2014. In 2017, he was selected as Shenzhen Peacock Overseas High-Caliber Personnel. Mr. Li has premium academic background and capital market experience at home and abroad.

     GHMSCB has carried out in-depth cooperation with many prestigious research institutes in China, including Shenzhen Institute of Advanced Technology CAS, Tongji University, Li Ka Shing Faculty of Medicine HKU, Shanghai East Hospital, and The First Affiliated Hospital of Guangzhou Medical University, in the field of joint laboratory construction, joint research projects and introduction of domestic and foreign high-tech talents.

     Enlife Institute was jointly founded by GHMSCB and Guangzhou Institute of Biomedicine and Health CAS in Aug 2018. It is supervised by Dongguan Science and Technology Bureau. At present, a phase I 4000 square meter laboratory has been built in strict accordance with national GMP standards and American AABB standards. The laboratory is equipped with world-class instruments and equipment, including laser confocal microscope produced by Zeiss (Germany), cryogenic storage tank BioArchive produced by GT (USA), FlowSight Imaging Flow Cytometer produced by Merck Millipore (Germany),Scientific Forma CryoMed Controlled produced by Thermo (USA), Automatic Blood Cell Analyzer produced by Mindray (China), etc.

     Enlife Institute has endeavored to bring in top experts from home and abroad. Scientists team includes: WeiHong Tan (Academician of the Chinese Academy of Sciences), ANTONIO VIDAL-PUIG (Academician of the British Academy of Medical Sciences, Professor of Cambridge University), JianXing He (Ph.D., Guangdong Cardiovascular Institute), ShaoRong Gao (Ph.D., Institute of Zoology CAS), ZhiHuan Li (Ph.D., University of Rochester, USA. Post-doctoral, Yale University & Harvard University, USA), JianBo Ruan (Famous Doctor in Dongguan, Dongguan Talents with Special Characteristics), JiuHong Kang (Winner of National Science Fund for Distinguished Young Scholars and Changjiang Scholars), Tiebang Kang (Distinguished Professor, Yangtze River Scholar of the Ministry of Education), JianChuan Xia (Research Associate of Harvard University), LinYong Zhu (Winner of National Science Fund for Distinguished Young Scholars and Oriental Scholars), XiaoChun Wan (Ph.D., University of Montreal, Canada), JunLei Chang (Ph.D., Harvard Medical School, USA), TongXiang Lin (Post-doctoral, University of California, San Diego), WenWen Jia (Ph.D., Northwest A&F University and University of Pennsylvania), LuJun Lou (Member of the Expert Group of the Southern Theater Air Force Hospital), ZhiLing Chen (Ph.D., Zurich Federal College of Science, Swiss; Ph.D., the European Centre for Nuclear Research), XingYin Liu (Post-doctoral, University of Rochester, USA & Albert Einstein College of Medicine),ROBERT KONRAD NAUMANN (Ph.D., Humboldt-University, Berlin, Germany; Post-doctoral, Max Planck Institute for Brain Research, Frankfurt, Germany), etc.

     At present, Enlife Institute has applied for a number of biotechnology invention patents, and obtained the authoritative cleanliness certification of GMP Laboratory of Guangzhou Institute of Microbiology and Dongguan Institute for Food and Drug Inspection. Meanwhile, it has passed ISO9001, ISO14001 and OHSAS18001 quality system certification. It means Enlife Institute has reached international standards in cell standardized preparation, safe storage and technical support. It has also been elected as deputy director unit of Guangdong Society for Cell Biology and admitted as a member of China Medicinal Biotech Association.

     In Aug 2019, Dongguan Municipal Health Bureau explicitly supported Enlife Institute to implement a 3-year strategic goal “2+5+2 Plan”, which means within the next 3 years, Enlife Institute will assist least 2 Dongguan hospitals to become registered stem cell clinical research institutions; it will allied with Dongguan hospitals to record 5 cell related projects with the National Health Commission; and it will cooperate with Dongguan hospitals to submit 2 clinical approval applications of new cellular drugs. The implementation of the plan is of great significance to promote the technological innovation, achievement transformation and industrial development of stem cells and regenerative medicine, and to promote the development of cell therapy in Dongguan City. At present, Enlife Institute has allied with a number of 3A hospitals and medical institutions in China to build a biological resource bank of regenerative medicine, striving to the realize the “Healthy China” dream. Alliances include 16 public hospitals such as: Shanghai East Hospital, the First Affiliated Hospital of Guangzhou Medical University, Dongguan People's Hospital, etc.


图片展示

企业文化

Company Culture

愿景

VISION

成为粤港澳大健康产业的创新驱动者

核心价值观

CORE VALUES

感恩、严谨、责任、创新、共享、服务

使命

MISSION

让人类更健康,更长寿

行为准则

PRINCIPLES OF CONDUCT

诚信、严谨、实事求是是使我们的行为准则

企业精神

Entrepreneurship

爱祖国、爱人民、爱事业和爱生活是我们凝聚力的源泉;责任意识、创新精神、敬业精神与团结合作精神是我们企业文化的精髓。愉悦争取,开心接受。

公司和研究院经营与研究范围包括

公司和研究院经营与研究范围包括

Scope Of Business And Research Of the Company And The ResearchInstitute Includes

图片展示

细胞储存

脐带干细胞、脂肪干细胞、胎盘干细胞、牙髓干细胞和免疫细胞的储存



图片展示

生物技术研发

细胞制备技术、细胞存储技术和相关试剂的研发



图片展示

细胞相关临床前研究

干细胞相关机理研究、细胞疗法、细胞药物研发、干细胞抗衰老研究等



图片展示

网站留言

官网“客户中心”——“联系我们”留言您的联系方式和需求,专属客服收到资料后将尽快与您联系。 

电话咨询

致电服务热线0769-28828333,将有专属客服为您服务。

公众号咨询

搜索“粤港澳干细胞”公众号关注留言您的联系方式等信息,我们尽快与您联系。

图片展示

网站留言

官网“客户中心”——“联系我们”留言您的联系方式和需求,专属客服收到资料后将尽快与您联系。 

电话咨询

致电服务热线0769-28828333,将有专属客服为您服务。

公众号咨询

搜索“粤港澳干细胞”公众号关注留言您的联系方式等信息,我们将第一时间与您联系。

图片展示

 Copyright © 粤港澳干细胞生物科技有限公司All Rights Reserved. 粤ICP备19082248号-1     网站地图